TY - T1的心血管和代谢危险因素发展的脑小血管疾病:纵向天赋成像在梅奥诊所研究衰老(p5.3 - 057) JF -神经学乔-神经学六世- 92 - 15补充SP - p5.3 - 057 AU -尤金Scharf盟乔纳森Graff-Radford AU -斯科特Przybelski盟David Knopman AU -格里高利Preboske AU -克里斯托弗•施瓦首页兹盟马修Senjem AU -杰弗瑞甘特盟Kejal Kantarci AU -米歇尔Mielke盟罗纳德·彼得森AU -克利福德杰克盟Prashanthi Vemuri Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p5.3 - 057. -文摘N2 -目的:确定心血管和代谢危险因素的影响(负责人)发展的白质高密度人口基数。背景:脑小血管疾病(CSVD)是一种血管性认知障碍的主要原因和混合社区老年痴呆;它可以评估的白质hyperintensities FLAIR-MRI(负责人)。越来越多的证据表明一个代谢疾病健康和负责人的发展之间的联系。然而,特定的心血管和代谢危险因素的影响发展的负责人是不完全理解。Design/Methods: This retrospective cohort included participants enrolled in the Mayo Clinic Study of Aging, a longitudinal population-based study in Olmsted County, Minnesota with at least 2 consecutive WMH assessments on FLAIR-MRIs (n=434 >=65 years with midlife assessments) with baseline measurements of body mass index, resting blood pressure, hemoglobin A1c, fasting glucose, and lipid panel. Mixed models were used to determine the specific components of baseline cardiometabolic risk associated with change in WMH normalized to total intracranial volume. These analyses were controlled for age and sex.Results: Age and female gender were associated with greater WMH (p<0.001). Baseline hypertension (p < 0.001), midlife hypertension (p=0.003), and baseline hemoglobin A1c (p=0.027) were predictive of increased WMH over follow up. High density lipoprotein (HDL), low density lipoprotein (LDL), triglycerides, and body mass index (BMI) were not associated with increased WMH. In sensitivity analyses, associations between hypertension and increased WMH progression were stronger in women.Conclusions: Hypertension (both mid and late life) and hemoglobin A1c were the strongest modifiable predictors associated with serial increases in WMH in this cohort. The association of hypertension and increased WMH was more pronounced in women. Further investigations should explore how changes in metabolic risk factors influence this aspect of CVSD.Disclosure: Dr. Scharf has nothing to disclose. Dr. Graff-Radford has nothing to disclose. Dr. Przybelski has nothing to disclose. Dr. Knopman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Washington University for the DIAN study. Dr. Knopman has received research support from Biogen Pharmaceuticals and Lilly Pharmaceuticals. Dr. Preboske has nothing to disclose. Dr. Schwarz has nothing to disclose. Dr. Senjem has nothing to disclose. Dr. Gunter has nothing to disclose. Dr. Kantarci has nothing to disclose. Dr. Mielke has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Lysosomal Therapeutics, Inc. Dr. Mielke has received research support from Biogen, Roche, and Lundbeck. Dr. Petersen has nothing to disclose. Dr. Jack has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lily. Dr. Vemuri has nothing to disclose. ER -